Allergic conjunctivitis: Treatment updates and long-term monitoring

Clara C. Chan; Caberry Yu

doi:10.58931/cait.2023.3357

Authors

Clara C. Chan, MD, FRCSC, FACS Department of Ophthalmology, University of Toronto
Caberry Yu, MD Department of Surgery, McMaster University, Hamilton, Ontario

DOI:

https://doi.org/10.58931/cait.2023.3357

Abstract

Allergic conjunctival diseases have a significant impact on the ocular surface, affecting the conjunctiva, cornea, and eyelids. Estimates indicate that approximately 35% of North Americans are affected by these diseases. Seasonal and perennial allergic conjunctivitis are the most common and mildest forms of ocular allergic disease, affecting 15–20% of the population. More severe conditions of ocular allergenic diseases include atopic keratoconjunctivitis (AKC), vernal keratoconjunctivitis (VKC), and giant papillary conjunctivitis (GPC). This article will review allergic conjunctivitis classifications, ocular sequelae, and a simplified treatment algorithm.

Author Biographies

Clara C. Chan, MD, FRCSC, FACS, Department of Ophthalmology, University of Toronto

Dr. Clara C. Chan is an Associate Professor of Ophthalmology at the University of Toronto and the President of the Canadian Cornea Society. She teaches fellows as part of the Cornea fellowship program and is the Medical Director of the Eye Bank of Canada, Ontario Division. After her undergraduate studies at Stanford University, she completed medical school at Queen’s University, ophthalmology residency at the University of Toronto, and her cornea fellowship at the Cincinnati Eye Institute with Dr. Edward Holland. Dr. Chan has published more than 140 peer-reviewed papers, received the American Academy of Ophthalmology Achievement Award in 2015, is a Cornea Section Editor for the Canadian Journal of Ophthalmology, and the Founding Editor of the journal, Canadian Eye Care Today. Most recently, Dr. Chan was included in The 2023 Ophthalmologist Power List, recognizing the top 100 most influential global figures in ophthalmology.

Caberry Yu, MD, Department of Surgery, McMaster University, Hamilton, Ontario

Dr. Caberry Yu is an Ophthalmology resident at McMaster University in Hamilton, Canada. She completed her medical degree from Queen’s University, where she was part of the Global Health Academic Enrichment Program. She is passionate about health for older adults and is a Junior Research Fellow at the National Institute on Ageing. Her research interests in ophthalmology include health equity and patient-reported outcome measures.

References

Dupuis P, Prokopich CL, Hynes A, Kim H. A contemporary look at allergic conjunctivitis. Allergy Asthma Clin Immunol. 2020;16:5. doi: 10.1186/s13223- 020-0403-9

Bielory L, Delgado L, Katelaris CH, Leonardi A, Rosario N, Vichyanoud P. ICON: Diagnosis and management of allergic conjunctivitis. Ann Allergy Asthma Immunol. 2020;124(2):118-134. doi: 10.1016/j.anai.2019.11.014

Bielory L, Skoner DP, Blaiss MS, Leatherman B, Dykewicz MS, Smith N, et al. Ocular and nasal allergy symptom burden in America: the Allergies, Immunotherapy, and RhinoconjunctivitiS (AIRS) surveys. Allergy Asthma Proc. 2014;35(3):211-218. doi: 10.2500/aap.2014.35.3750

Kimchi N, Bielory L. The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents. Curr Opin Allergy Clin Immunol. 2020;20(4):414-420. doi: 10.1097/ACI.0000000000000669

Rodrigues J, Kuruvilla ME, Vanijcharoenkarn K, Patel N, Hom MM, Wallace DV. The spectrum of allergic ocular diseases. Annals of Allergy, Asthma & Immunology. 2021 1;126(3):240-254. doi: 10.1016/j.anai.2020.11.016

Leonardi A, De Dominicis C, Motterle L. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol. 2007;7(5):429-435. doi: 10.1097/ACI.0b013e3282ef8674

Fukuda K, Kishimoto T, Sumi T, Yamashiro K, Ebihara N. Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye. Allergol Int. 2023;72(2):234-244. doi: 10.1016/j.alit.2022.09.005

Guglielmetti S, Dart JK, Calder V. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol. 2010;10(5):478-485. doi: 10.1097/ ACI.0b013e32833e16e4

Abbehdari S, Starnes TW, Kurji KH, Eslani M, Cortina MS, Holland EJ, et al. Management of advanced ocular surface disease in patients with severe atopic keratoconjunctivitis. Ocul Surf. 2019;17(2):303-309. doi: 10.1016/j.jtos.2018

Seth I, Bulloch G, Vine M, Outmezguine J, Seth N, Every J, et al. The association between keratoconus and allergic eye diseases: a systematic review and meta-analysis. Clin Exp Ophthalmol. 2023;51(4):O1-O16. doi: 10.1111/ ceo.14215

Deng SX, Borderie V, Chan CC, Dana R, Figueiredo FC, Gomes JAP, et al. Global consensus on definition, classification, diagnosis, and staging of limbal stem cell deficiency. Cornea. 2019;38(3):364-375. doi: 10.1097/ ICO.0000000000001820

Health Canada. Drug Product Database online query [Internet]. 2023. [Updated May 25, 2023, Cited, October 24, 2023]. Available from: https://health-products. canada.ca/dpd-bdpp/

Government of Canada. The Drug and Health Product Register [Internet]. 2021. [Updated July 14, 2021; Cited October 24, 2023]. Available from: https://hpr- rps.hres.ca/index.php

Wade L, Bielory L, Rudner S. Ophthalmic antihistamines and H1-H4 receptors. Curr Opin Allergy Clin Immunol. 2012 t;12(5):510-516. doi: 10.1097/ ACI.0b013e328357d3ba

Meier EJ, Torkildsen GL, Gomes PJ, Jasek MC. Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model. Clin Ophthalmol. 2018;12:2617-2628. doi: 10.2147/OPTH.S185835

Labib BA, Chigbu DI. Therapeutic targets in allergic conjunctivitis. Pharmaceuticals (Basel). 2022 28;15(5):547. doi: 10.3390/ph15050547

Bielory BP, Perez VL, Bielory L. Treatment of seasonal allergic conjunctivitis with ophthalmic corticosteroids: in search of the perfect ocular corticosteroids in the treatment of allergic conjunctivitis. Curr Opin Allergy Clin Immunol. 2010;10(5):469-477. doi: 10.1097/ACI.0b013e32833dfa28

Congdon NG, Schein OD, Von Kulajta P, Lubomski LH, Gilbert D, Katz J. Corneal complications associated with topical ophthalmic use of nonsteroidal antiinflammatory drugs. J Cataract Refract Surg. 2001;27(4):622-631. doi: 10.1016/s0886-3350(01)00801-x

The use of newer asthma and allergy medications during pregnancy. The American College of Obstetricians and Gynecologists (ACOG) and The American College of Allergy, Asthma and Immunology (ACAAI). Ann Allergy Asthma Immunol. 2000;84(5):475-480.

Leonardi A, Doan S, Amrane M, Ismail D, Montero J, Németh J, et al. A randomized, controlled trial of cyclosporine a cationic emulsion in pediatric vernal keratoconjunctivitis: the VEKTIS Study. Ophthalmology. 2019;126(5):671- 681. doi: 10.1016/j.ophtha.2018.12.027

Whitcup SM, Chan CC, Kozhich AT, Magone MT. Blocking ICAM-1 (CD54) and LFA-1 (CD11a) inhibits experimental allergic conjunctivitis. Clin Immunol. 1999;93(2):107-113. doi: 10.1006/clim.1999.4775

Felfeli T, Georgakopoulos JR, Jo CE, Mimouni M, Piguet V, Drucker AM, et al. Prevalence and characteristics of dupilumab-induced ocular surface disease in adults with atopic dermatitis. Cornea. 2022 1;41(10):1242-1247. doi: 10.1097/ ICO.0000000000002866

Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy. 2017;72(11):1597-1631. doi: 10.1111/all.13201

Valenzuela CV, Liu JC, Vila PM, Simon L, Doering M, Lieu JEC. Intranasal corticosteroids do not lead to ocular changes: a systematic review and meta-analysis. Laryngoscope. 2019;129(1):6-12. doi: 10.1002/lary.27209

Clark D, Cavanagh B, Shields AL, Karpecki P, Sheppard J, Brady TC. Clinically relevant activity of the novel rasp inhibitor reproxalap in allergic conjunctivitis: the Phase 3 ALLEVIATE Trial. Am J Ophthalmol. 2021;230:60-67. doi: 10.1016/j. ajo.2021.04.023

McLaurin EB, Evans D, Repke CS, Sato MA, Gomes PJ, Reilly E, et al. Phase 3 randomized study of efficacy and safety of a dexamethasone intracanalicular insert in patients with allergic conjunctivitis. Am J Ophthalmol. 2021;229:288- 300. doi: 10.1016/j.ajo.2021.03.017

Allergic conjunctivitis: Treatment updates and long-term monitoring

Authors

DOI:

Abstract

Author Biographies

Clara C. Chan, MD, FRCSC, FACS, Department of Ophthalmology, University of Toronto

Caberry Yu, MD, Department of Surgery, McMaster University, Hamilton, Ontario

References

Downloads

Published

How to Cite

Issue

Section

Summary

Open Access

Licence